Print

87 I-114

A Toxicity / Immunogenicity Study of a Recombinant HIV-Envelope Protein (gp160).

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) October 01, 1989
gp160 Vaccine (Immuno-AG) env gp160
gp160 Vaccine (Immuno-AG) Protein
USA
http://www.actis.org